These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 9355964)

  • 41. Modulation of peripheral leukocyte counts in mice by oral administration of interferons.
    Fleischmann WR; Fields EE; Wang JL; Hughes TK; Stanton GJ
    Proc Soc Exp Biol Med; 1991 Sep; 197(4):424-30. PubMed ID: 1714606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased susceptibility to pentobarbital following mouse cytomegalovirus infection: relative roles of viral-induced interferon and viral infection of the liver.
    Catignani JC; Ménache MG; Selgrade MK
    J Biochem Toxicol; 1989; 4(4):221-9. PubMed ID: 2483849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic potential for orally administered type 1 interferons.
    Beilharz MW
    Pharm Sci Technol Today; 2000 Jun; 3(6):193-197. PubMed ID: 10840389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future.
    Frazzini S; Riva F; Amadori M
    Vet Sci; 2021 Jun; 8(6):. PubMed ID: 34208413
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon as a Mucosal Adjuvant for an Influenza Vaccine in Pigs.
    Liu L; Fan W; Zhang H; Zhang S; Cui L; Wang M; Bai X; Yang W; Sun L; Yang L; Liu W; Li J
    Virol Sin; 2019 Jun; 34(3):324-333. PubMed ID: 30989429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-dose oral interferon modulates expression of inflammatory and autoimmune genes in cattle.
    Mamber SW; Lins J; Gurel V; Hutcheson DP; Pinedo P; Bechtol D; Krakowka S; Fields-Henderson R; Cummins JM
    Vet Immunol Immunopathol; 2016 Apr; 172():64-71. PubMed ID: 27032505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse.
    Lee CM; Chen CY; Chien RN; Tseng KC; Peng CY; Tung SY; Fang YJ; Huang YH; Lu SN; Hung CH; Tsai TJ; Fang CC; Hsu CW; Yeh CT
    J Interferon Cytokine Res; 2014 Mar; 34(3):187-94. PubMed ID: 24237300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year.
    Bennett AL; Smith DW; Cummins MJ; Jacoby PA; Cummins JM; Beilharz MW
    Influenza Other Respir Viruses; 2013 Sep; 7(5):854-62. PubMed ID: 23398960
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced interferon (IFN)-α conditioned by IFNA2 (-173) and IFNA8 (-884) haplotypes is associated with enhanced susceptibility to severe malarial anemia and longitudinal all-cause mortality.
    Kempaiah P; Anyona SB; Raballah E; Davenport GC; Were T; Hittner JB; Ong'echa JM; Perkins DJ
    Hum Genet; 2012 Aug; 131(8):1375-91. PubMed ID: 22570109
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells.
    Monini P; Carlini F; Stürzl M; Rimessi P; Superti F; Franco M; Melucci-Vigo G; Cafaro A; Goletti D; Sgadari C; Butto' S; Leone P; Chiozzini C; Barresi C; Tinari A; Bonaccorsi A; Capobianchi MR; Giuliani M; di Carlo A; Andreoni M; Rezza G; Ensoli B
    J Virol; 1999 May; 73(5):4029-41. PubMed ID: 10196299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The IFN regulatory factor 7-dependent type I IFN response is not essential for early resistance against murine cytomegalovirus infection.
    Steinberg C; Eisenächer K; Gross O; Reindl W; Schmitz F; Ruland J; Krug A
    Eur J Immunol; 2009 Apr; 39(4):1007-18. PubMed ID: 19283778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Balancing viral replication in spleen and liver determines the outcome of systemic virus infection.
    Lang KS; Lang PA
    Z Gastroenterol; 2015 Dec; 53(12):1432-5. PubMed ID: 26666281
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo.
    Beilharz MW; McDonald W; Watson MW; Heng J; McGeachie J; Lawson CM
    J Interferon Cytokine Res; 1997 Oct; 17(10):625-30. PubMed ID: 9355964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo.
    Bosio E; Beilharz MW; Watson MW; Lawson CM
    J Interferon Cytokine Res; 1999 Aug; 19(8):869-76. PubMed ID: 10476931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. STAT2-Dependent Immune Responses Ensure Host Survival despite the Presence of a Potent Viral Antagonist.
    Le-Trilling VTK; Wohlgemuth K; Rückborn MU; Jagnjic A; Maaßen F; Timmer L; Katschinski B; Trilling M
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low-dose oral use of interferon inhibits virally induced myocarditis.
    Lawson CM; Beilharz MW
    J Interferon Cytokine Res; 1999 Aug; 19(8):863-7. PubMed ID: 10476930
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.